HETE is the endogenous agonist for G protein-coupled receptor 39 (GPR39) in vascular smooth cells, so researchers ...

The enzyme aminocarboxymuconate semialdehyde decarboxylase (ACMSD) is a regulator of de novo NAD+ synthesis and is reduced in ...

Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition ...

To address limitations with CAR T therapies targeting CD19, Allogene Therapeutics Inc. has developed ALLO-329, a ...

Oxford Nanopore Technologies Ltd. has established a new collaboration with UK Biobank to create the world’s first ...

Our immune cells are not just “defenders” against deadly viruses and pathogens but also a great balancer for tissue ...

The FDA announced a new pilot program for communication of medical device recalls, but industry may be wary of a program that ...

The first day of the U.S. FDA’s two-day advisory hearing on generative artificial intelligence reflected some of the ...

Previous laboratory and clinical studies showed that inhibiting the activation of the MAPK signaling pathway could attenuate acute lung injury.

Researchers at the University of Copenhagen have identified a signaling pathway that simultaneously increased energy expenditure and decreased food intake. In both human and primate studies, agonists ...

Researchers from Anaveon AG and affiliated organizations presented the discovery and preclinical characterization of ANV-700, a novel proximity-activated cytokine (PAC) compound designed to ...

Empyrean Therapeutics Inc. has acquired a first-in-class TLR2 antagonist molecule from Eos Therapies Inc. with the aim of ...